Generic drug products in paediatrics: Where are the data?

Sílvia M. Illamola; Angela K. Birnbaum; Catherine M. Sherwin

doi:10.1111/bcp.14036

Generic drug products in paediatrics: Where are the data?

Sílvia M. Illamola, Angela K. Birnbaum, Catherine M. Sherwin

Wright State University

Research output: Contribution to journal › Editorial › peer-review

Abstract

<p> The use of generic drugs can significantly decrease costs while providing equivalent therapeutic efficacy, thus increasing access to medications. This can be of special interest for some high&hyphen;cost medications and those used in chronic therapy (eg, immunosuppressive agents, oncology drugs, and antiepileptic drugs). The Food and Drug Administration (FDA) defines a generic drug as being “the same as a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use.” <sup> 1 </sup></p>

Original language	English
Pages (from-to)	1871-1873
Number of pages	3
Journal	British Journal of Clinical Pharmacology
Volume	85
Issue number	9
DOIs	https://doi.org/10.1111/bcp.14036
State	Published - Sep 1 2019

ASJC Scopus Subject Areas

Pharmacology
Pharmacology (medical)

Keywords

bioavailability
bioequivalence
drug regulation
drug utilization
paediatrics

Disciplines

Medical Specialties
Medicine and Health Sciences
Pediatrics

Access to Document

10.1111/bcp.14036

https://doi.org/10.1111/bcp.14036

Cite this

@article{c097b542e6f4464aad6112dcb8cce37a,

title = "Generic drug products in paediatrics: Where are the data?",

abstract = " The use of generic drugs can significantly decrease costs while providing equivalent therapeutic efficacy, thus increasing access to medications. This can be of special interest for some high&hyphen;cost medications and those used in chronic therapy (eg, immunosuppressive agents, oncology drugs, and antiepileptic drugs). The Food and Drug Administration (FDA) defines a generic drug as being “the same as a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use.” 1 ",

keywords = "bioavailability, bioequivalence, drug regulation, drug utilization, paediatrics",

author = "Illamola, {S{\'i}lvia M.} and Birnbaum, {Angela K.} and Sherwin, {Catherine M.}",

year = "2019",

month = sep,

day = "1",

doi = "10.1111/bcp.14036",

language = "English",

volume = "85",

pages = "1871--1873",

journal = "British Journal of Clinical Pharmacology",

issn = "0306-5251",

number = "9",

}

TY - JOUR

T1 - Generic drug products in paediatrics

T2 - Where are the data?

AU - Illamola, Sílvia M.

AU - Birnbaum, Angela K.

AU - Sherwin, Catherine M.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The use of generic drugs can significantly decrease costs while providing equivalent therapeutic efficacy, thus increasing access to medications. This can be of special interest for some high&hyphen;cost medications and those used in chronic therapy (eg, immunosuppressive agents, oncology drugs, and antiepileptic drugs). The Food and Drug Administration (FDA) defines a generic drug as being “the same as a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use.” 1

AB - The use of generic drugs can significantly decrease costs while providing equivalent therapeutic efficacy, thus increasing access to medications. This can be of special interest for some high&hyphen;cost medications and those used in chronic therapy (eg, immunosuppressive agents, oncology drugs, and antiepileptic drugs). The Food and Drug Administration (FDA) defines a generic drug as being “the same as a brand name drug in dosage, safety, strength, how it is taken, quality, performance, and intended use.” 1

KW - bioavailability

KW - bioequivalence

KW - drug regulation

KW - drug utilization

KW - paediatrics

UR - http://www.scopus.com/inward/record.url?scp=85068661020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068661020&partnerID=8YFLogxK

UR - https://corescholar.libraries.wright.edu/pediatrics/363

UR - https://doi.org/10.1111/bcp.14036

U2 - 10.1111/bcp.14036

DO - 10.1111/bcp.14036

M3 - Editorial

C2 - 31281980

AN - SCOPUS:85068661020

SN - 0306-5251

VL - 85

SP - 1871

EP - 1873

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

IS - 9

ER -

Generic drug products in paediatrics: Where are the data?

Abstract

ASJC Scopus Subject Areas

Keywords

Disciplines

Access to Document

Other files and links

Cite this